To the Editor In the May 2016 issue of JAMA Dermatology, Mohan et al1 report an increased risk of cutaneous squamous cell carcinoma (CSCC) after vismodegib therapy for basal cell carcinoma (BCC).1 They collected data from a cohort of 55 patients with BCC treated with vismodegib and compared the risk of CSCC with that in a cohort of 125 patients with BCC not treated with vismodegib. The authors present the study as a case-control study, which it is not.
Gjersvik P. Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell CarcinomaNot a Case-Control Study. JAMA Dermatol. 2016;152(10):1172. doi:10.1001/jamadermatol.2016.2427